Skip to main content
OpenTrials

Clinical trial condition

Stargardt Disease

Explore clinical trials studying Stargardt Disease. Study availability and eligibility vary by location and protocol.

56 public trials 20 recruiting studies
Refine in advanced search Browse all conditions

Stargardt Disease trial results

Recruiting

Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

NCT06445322

Conditions
Cone Rod Dystrophy, Cone-Rod Dystrophies, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +10 more
Locations
  • University of San Francisco San Francisco, California, United States
  • Vitreo Retinal Associates Gainesville, Florida, United States
  • Wilmer Eye Institute at John Hopkins Baltimore, Maryland, United States
  • Massachusetts Eye and Ear Boston, Massachusetts, United States
View Trial Details
Recruiting

Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

NCT06467344

Conditions
Cone Rod Dystrophy, Cone-Rod Dystrophies, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +10 more
Locations
  • University of San Francisco San Francisco, California, United States
  • Vitreo Retinal Associates Gainesville, Florida, United States
  • Bascom Palmer Eye Institute Miami, Florida, United States
  • Wilmer Eye Institute at John Hopkins Baltimore, Maryland, United States
View Trial Details
Recruiting

An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

NCT06435000

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases, Eye Diseases, Hereditary, +8 more
Locations
  • Shiley Eye Institute San Diego, California, United States
  • UCHealth Sue Anschutz-Rodgers Eye Center Aurora, Colorado, United States
  • Vitreo Retinal Associates Gainesville, Florida, United States
  • Bascom Palmer Eye Institute Miami, Florida, United States
View all 20 locations
View Trial Details
Recruiting

A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)

NCT06942572

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases, Eye Diseases, Hereditary, +7 more
Locations
  • UCHealth Sue Anschutz-Rodgers Eye Center, Aurora, Colorado, United States
  • Bascom Palmer Eye Institute Miami, Florida, United States
  • Massachusetts Eye and Ear Infirmary Boston, Massachusetts, United States
  • Oregon Health & Science University Portland, Oregon, United States
View Trial Details

Related conditions